BCTX

0.789

29.50% 0.1867

Dopo l'orario di chiusura: .77 -0.019 -2.41%

Briacell Therapeutics Corp (BCTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.6023

Aprire:

$0.6185

Volume 24 ore:

4.01M

Relative Volume:

0.83

Capitalizzazione di mercato:

$28.58M

Reddito:

Utile/perdita netta:

$-6.00M

Rapporto P/E:

-5.8969

EPS:

-0.1338

Flusso di cassa netto:

$-31.01M

1 W Prestazione:

+31.09%

1M Prestazione:

-2.03%

6M Prestazione:

-47.65%

1 anno Prestazione:

-82.47%

Intervallo 1D:

$0.61

$0.8212

Intervallo di 1 settimana:

$0.555

$0.8212

Portata 52W:

$0.4641

$5.97

Briacell Therapeutics Corp Stock (BCTX) Company Profile

Nome

Briacell Therapeutics Corp

Settore

Healthcare (1196)

Industria

Biotechnology (683)

Telefono

(604) 921-1810

Indirizzo

3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER

Dipendente

Cinguettio

Prossima data di guadagno

2024-10-28

Ultimi documenti SEC

BCTX's Discussions on Twitter

Confronta BCTX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCTX	0.789	28.58M	0	-6.00M	-31.01M	-0.1338
VRTX	450.37	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	744.50	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	596.74	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.80	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	108.23	24.89B	3.30B	-501.07M	1.03B	11.54

Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-02-14	Iniziato	H.C. Wainwright	Buy

Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie

01:06 AM

BriaCell begins phase 1/2 trial of Bria-OTS™ for breast cancer | 2024-11-21 | Investing News - Stockhouse Publishing

01:06 AM

07:51 AM

BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study - GlobeNewswire

07:51 AM

07:50 AM

BriaCell Launches Phase 1/2 Trial of Next-Gen Breast Cancer Immunotherapy | BCTX Stock News - StockTitan

07:50 AM

Nov 13, 2024

Closing Bell: Briacell Therapeutics Corp Down On Monday (BCT) - Barchart

Nov 13, 2024

Nov 08, 2024

BriaCell Showcases Robust Anti-Cancer Activity of - GlobeNewswire

Nov 08, 2024

BriaCell's Next-Gen Cancer Immunotherapies Show Breakthrough Results in Preclinical Data | BCTX Stock News - StockTitan

Nov 08, 2024

Nov 04, 2024

BriaCell Overall Survival Data Selected for Spotlight - GlobeNewswire

Nov 04, 2024

BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13 - StockTitan

Nov 04, 2024

Nov 01, 2024

BriaCell Therapeutics Faces Uncertain Financial Future - TipRanks

Nov 01, 2024

Oct 28, 2024

BriaCell Therapeutics Corp. Reports Earnings Results for the Full Year Ended July 31, 2024 - Marketscreener.com

Oct 28, 2024

Oct 22, 2024

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns - Seeking Alpha

Oct 22, 2024

BriaCell reports survival data from Phase 2 study | 2024-10-22 | Investing News - Stockhouse Publishing

Oct 22, 2024

BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data - GlobeNewswire

Oct 22, 2024

Oct 16, 2024

You might want to take a look at BriaCell Therapeutics Corp (BCTX) now - SETE News

Oct 16, 2024

Oct 15, 2024

BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study - GlobeNewswire

Oct 15, 2024

BriaCell Therapeutics advances Phase 3 MBC clinical study | 2024-10-15 | Investing News - Stockhouse Publishing

Oct 15, 2024

BCTX’s 52-Week Rollercoaster: From $0.46 to $5.97 – What’s Next for Investors? - The InvestChronicle

Oct 15, 2024

Analyzing BriaCell Therapeutics Corp (BCTX) After Recent Trading Activity - Knox Daily

Oct 14, 2024